Live feed07:00:00·928dPRReleasevia QuantisnowVanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple SclerosisByQuantisnow·Wall Street's wire, on your screen.VNDA· Vanda Pharmaceuticals Inc.Health Care
